FIBROGEN INVESTOR ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ:FGEN).
If you suffered losses exceeding $50,000 investing in FibroGen stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also fill out the form below for additional information.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.
On April 6, 2021, after the market closed, FibroGen issued a statement admitting that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. Specifically, the Company stated: "As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors… we promptly decided to clarify this issue with the FDA and communicate with the scientific and investment communities.”
* The submission of this form does not create an attorney-client relationship.
Filed on 04/07/2021
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
James M. Wilson, Jr. email@example.com Phone (212) 983-9330 Fax (212) 983-9331
Robert W. Killorin firstname.lastname@example.org Phone (404) 847-0617 Fax (404) 506-9534